Increased disruption from multiple fronts is changing the pharmacy supply chain and transforming your IDN. Breakthroughs are occurring at a record pace, building on the power of AI, robotics, new market entrants, and increased government regulation, are just a few of the challenges you are having to confront. Shifting from imprecision medicine to precision treatments, from a fee-for-service reimbursement model to a value-based model, changing the role of the IDN pharmacist and the delivery channels we know today. 

Join these three GPO leaders as they discuss how the changing landscape will impact your IDN. Bring your questions because there will be ample time for audience engagement.

Learning Objectives
1. Identify strategies to combat new entrants impacting your IDN pharmacy.

2. Outline opportunities to improve your organization’s operation through new innovations.

3. Evaluate the impact of shifting treatment models on the role of your IDN pharmacists.

4. Prepare your organization for changes in regulation and reimbursement.

View Slides

Listen to Audio

The 340B Program faces challenges from both suppliers and payers. Dozens of drug manufacturers have unilaterally blocked shipment of 340B drugs to “contract pharmacies”, i.e., independent, chain and/or mail order pharmacies under contract with 340B hospitals and clinics to receive and dispense 340B drugs on their behalf. Meanwhile, pharmacy benefit managers and other payers have cut reimbursement to 340B pharmacies or subjected them to other restrictive contracting practices. These threats have led to a proliferation of federal lawsuits and calls for reform by some members of Congress, but resolution is still years away. Frustrated with federal inaction, state legislatures have jumped into the fray by passing laws that, on the one hand, protect 340B contract pharmacy arrangements and prohibit discriminatory contracting by payers and, on the other, subject 340B providers to greater transparency and accountability. Our speakers will summarize and analyze these federal and state 340B developments, their impact on the supply chain and reimbursement practices, and where these trends are likely to lead. 

Learning Objectives

1. Describe current legislative and litigation activities at the federal and state levels that will likely shape the future of the 340B Program.

2. Analyze the implications of these program trends on the supply chain and third party payers.

3. Evaluate strategies available to 340B hospitals and clinics for mitigating current threats.

4. Identify future threats to the 340B Program and solutions for your organization.

View Slides

Listen to Audio

Designed to enhance the safety and security of the United States pharmaceutical supply chain, the DSCSA plays a critical part in safeguarding patients by ensuring drug supply chain integrity. This is accomplished through interoperable, electronic package tracing, annual licensure reports from wholesale distributors and third-party logistics providers, and other regulatory tools that aide in the detection and removal of dangerous drugs from the supply chain.

Join industry thought leader(s) as they discuss DSCSA initiatives to prioritize patient well-being and supply chain integrity in collaboration with the Food and Drug Administration (FDA). Break down obstacles to patient safety such as counterfeit, stolen, or contaminated drugs including recalls and how these obstacles can be overcome.

Learning Objectives
1. Define how scanning the DSCSA Product Identifier enhances patient safety at your IDN. 
2. Outline methods of ensuring security within the pharmacy supply chain that suggest focus on FDA’s recent final guidance” and compliance policy “Enhanced Drug Distribution Security Requirements.”
3. Review the FDA’s latest final guidance on verification systems under DSCSA that manufacturers, repackagers, wholesale distributors and dispensers must have in place for potential future threats to the integrity of your pharmacy supply chain.
4. Discuss methods for confirming the entities you do business with are licensed or registered.

View Slides

Listen to Audio